Clinical Trials Browser

Recurrence × zimberelimab × 90 days × Clear all

NCT04656535 2026-04-17

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Recurrence